The S&P 500 (^GSPC) erased losses of as much as 1% to rise just above the flatline. The Dow Jones Industrial Average (^DJI) edged up 0.3%, notching its longest win streak of 2025. Both indexes ...

The S&P 500 is still in correction territory, but it will likely climb out of it if the trade policy becomes less aggressive. Given what Trump is saying, that’s pretty likely, but not impossible.

Reform UK could scoop more than 500 council seats at this week's local elections, according to a leading expert. Nigel Farage's party have consistently outperformed the Tories in recent national ...

A topsy-turvy day ended with the S&P 500 back in the green. As the closing bell struck, the index and the ETF both ended “up” by the narrowest of margins, less than 0.1%, but positive.

In fact, A 2024 YouGov survey showed the average UK adult spends £39 a month on subscriptions — that's just under £500 per year The problem: When streaming first became a thing, having one or ...

Hundreds of fat-cat public officials were paid more than the Prime Minister last year – sparking calls for Labour to speed up its promised 'bonfire of the quangos'. More than 350 quango bosses ...

David Socks, Phathom co-founder and Director will retire from the Board at the upcoming Annual Shareholders Meeting on June 3, 2025. Phathom is implementing a significant cost reduction and ...

For both my children, I can look to be spending £300 just on the branded logo items and up to £500 for everything ... emailing [email protected].

Our writer wasn’t surprised to see AJ Bell investors buying into the S&P 500 earlier this month, though one popular UK share did raise his eyebrow. When investing, your capital is at risk.

The trio have racked up nearly 500 Liverpool appearances between them - Gomez 241, Nunez 139 and Tsimikas 113 - but the Telegraph suggest they won't be making too many more as Slot reshuffles his ...

FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for ...